Evidence map›Paper›PMID 42828281›Full record

ArticleBioactive materials2027

In situ bioactive nanocoating enables transocular delivery of permeable drug for dual-location intervention of ocular surface and fundus disorders.

Zeqi Wang, Wenyan Lv, Yun Su, Tengteng Yao, Yue Lu, Chuhan Wang, Chuqiao Wang, Yu Yu, Jin Chen, Qiaoran Qi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zeqi WangShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Wenyan LvState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Yun SuShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Tengteng YaoShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Yue LuShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmacy, Shanghai Jiao Tong University, 200240, China.
Chuhan WangShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Chuqiao WangShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Yu YuShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Jin ChenShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Qiaoran QiShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Yan PangShanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Center for Basic Medical Research and Innovation in Visual System Diseases, Ministry of Education, State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
Zhaoyang WangBeijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Feng WuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concurrency of ocular surface and fundus disorders is prevalent, posing a major threat to vision and quality of life. However, current therapies are difficult to simultaneously manage these coexisting symptoms. Here, we report a dual-location intervention strategy by in situ forming a permeable drug-carried bioactive nanocoating on ocular surface following instillation. The nanocoating is readily generated via dropping a mixture of polyphenol, metal ions, liposomes, and permeable drug. The coordination of metal ions with polyphenol and lipid enables nanocoating formation and its durable adhesion to ocular surface. The introduced bioactive polyphenol and liposomes separately provide anti-inflammatory activity and tear film-forming lipid to synergistically alleviate ocular surface disorder. In addition, the resulted network structure of the nanocoating offers continuous release of permeable drug, achieving intraocular delivery to mitigate the fundus symptom. Supported by the potency in synchronously intervening diabetic keratopathy and retinopathy in both streptozotocin-induced and Ins2-C96Y transgenic mouse models, this work opens a window for treating ocular diseases.

Indexed as

Drug deliveryNanocoatingOcular fundusOcular surfaceTopical administration

Identifiers

PMID42828281
PMCPMC13632224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.